Scarica l'app Stockscreener
63.04
1.08%
-0.69
Dopo l'orario di chiusura:
62.00
-1.04
-1.65%
Precedente Chiudi:
$63.73
Aprire:
$64
Volume 24 ore:
6.01M
Relative Volume:
2.75
Capitalizzazione di mercato:
$6.62B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+20.05%
1M Prestazione:
+20.47%
6M Prestazione:
+161.47%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$62.48
$64.33
Intervallo di 1 settimana:
$51.84
$66.10
Portata 52W:
$12.30
$66.10
Metsera Inc Stock (MTSR) Company Profile
Nome
Metsera Inc
Settore
Industria
Telefono
(212) 784-6595
Indirizzo
3 WORLD TRADE CENTER, NEW YORK
Confronta MTSR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
63.04 | 6.71B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-09-09 | Iniziato | Leerink Partners | Outperform |
| 2025-06-20 | Iniziato | Wells Fargo | Overweight |
| 2025-02-25 | Iniziato | BofA Securities | Buy |
| 2025-02-25 | Iniziato | Evercore ISI | Outperform |
| 2025-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Metsera Inc Borsa (MTSR) Ultime notizie
Key facts: Pfizer to report Q3 earnings on Nov 4; faces legal battle over Metsera - TradingView
Metsera Inc. stock chart pattern explainedJuly 2025 Opening Moves & Free Weekly Watchlist of Top Performers - newser.com
Why Metsera Inc. stock attracts global investorsWall Street Watch & Low Risk High Reward Ideas - newser.com
Pfizer sues to block Novo Nordisk's Metsera takeover bid - pharmaphorum
Real Madrid to Seek Damages After Antitrust Ruling Against UEFA - PYMNTS.com
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk - MSN
Novo Nordisk submits proposal to acquire Metsera - Medical Dialogues
The week in pharma: action, reaction and insight – week to October 31 - The Pharma Letter
Why Pfizer Can Still Prevail in the Obesity Fight With Novo NordiskWSJ - The Wall Street Journal
What Fibonacci levels say about Metsera Inc. reboundAnalyst Downgrade & Entry and Exit Point Strategies - newser.com
Metsera Inc. $MTSR Shares Sold by Jennison Associates LLC - MarketBeat
Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera - MSN
Is Metsera Inc. forming a bottoming baseStop Loss & Technical Pattern Based Signals - newser.com
Key facts: Pfizer gains antitrust approval for Metsera; faces lawsuits - TradingView
Pfizer sues Metsera, Novo in effort to enforce buyout deal - BioPharma Dive
Pfizer Sues Metsera to Block Novo Nordisk’s $9B “Bribe” Deal - USA Herald
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid - RNZ
Pfizer goes to court to stop Novo Nordisk bid for Metsera - The Pharma Letter
Is Metsera Inc. building a consolidation base2025 Analyst Calls & Fast Entry High Yield Stock Tips - newser.com
Novo makes a play for Metsera; This week’s other big deal; Earnings in full swing; and more - Endpoints News
Pfizer sues to block Novo Nordisk’s bid for Metsera in high-stakes pharma clash - TradingView
Pfizer Sues to Block Novo Bid for Obesity Drugmaker Metsera - MSN
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer - MSN
Pfizer Sues Metsera, Novo Nordisk Over $9B Buyout 'Bribe' - Law360
Key facts: Novo Nordisk bids $9B for Metsera; job cuts near completion - TradingView
Pfizer secures early termination, launches lawsuit over Metsera deal - Global Competition Review
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark’s Novo Nordisk - CBS 42
Pfizer files lawsuit to block Novo Nordisk's bid for Metsera - Axios
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid By Reuters - Investing.com
Metsera (MTSR) Responds to Pfizer's Legal Action - GuruFocus
Pfizer Sues Seeking to Block Novo Nordisk’s Effort to Undo Weight-Loss Drug DealWSJ - The Wall Street Journal
Pfizer Gets Nod to Proceed With Metsera Deal From US Regulators - Bloomberg.com
Pfizer Sues Novo, Metsera Over $6.5 Billion Bid - Investor's Business Daily
Metsera Issues Statement in Response to Litigation - Yahoo Finance
Pfizer (PFE) Sues Metsera and Novo Nordisk Over Disputed Obesity Drug Merger - TipRanks
Pfizer sues Novo Nordisk, Metsera for breach of merger agreement - statnews.com
Pfizer sues Metsera and Novo Nordisk over merger agreement breach - Investing.com
Pfizer Files Lawsuit Against Metsera And Its Directors And Novo Nordisk For Breach Of Merger Agreement - TradingView
Pfizer sues Metsera, Novo Nordisk for merger deal breach - breakingthenews.net
Pfizer (PFE) Granted Early Termination for Metsera Acquisition - GuruFocus
Pfizer sues Metsera and Novo Nordisk over merger agreement breach By Investing.com - Investing.com Nigeria
Pfizer sues Metsera, Novo Nordisk over breach of merger deal By Reuters - Investing.com
Pfizer sues Metsera, Novo Nordisk over breach of merger deal - Reuters
Novo Nordisk (NVO) in Pursuit of Metsera Amid Pfizer's Regulator - GuruFocus
Pfizer wins early US antitrust nod for Metsera deal - Yahoo Finance
Pfizer/Metsera secures early termination - Global Competition Review
Pfizer sues to stop Novo’s Metsera takeover attempt - Endpoints News
Battle for obesity biotech Metsera heats up as Pfizer sues to block rival bid - Financial Times
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement - Business Wire
Metsera Inc Azioni (MTSR) Dati Finanziari
Non sono disponibili dati finanziari per Metsera Inc (MTSR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):